Skip to content

Study · Observational study · n = 5,147 · 2016

7 results

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Milicevic Z, Anglin G, Harper K, Konrad RJ, Skrivanek Z, Glaesner W, Karanikas CA, Mace K

Diabetes, obesity & metabolism4 Mar 2016Cited by 22 (Europe PMC)

PMID26847401 (opens in a new tab)DOI10.1111/dom.12640 (opens in a new tab)PepBankPUB-26847401
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studySafety outcome

    Dulaglutide anti-drug antibodies occurred in 1.6% of treated patients versus 0.7% with non-GLP-1 comparators.

    In plain wordsDrug antibodies occurred in 1.6% with dulaglutide versus 0.7% with other non-GLP-1 treatments.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTreatment-emergent anti-drug antibodies
    Study

    n = 5,147

    Comparator
    Non-GLP-1 comparators
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    ADA-positive patients
    64 patients
    dulaglutide
    ADA incidence
    1.6%
    dulaglutide
    ADA-positive patients
    8 patients
    non-GLP-1 comparators
    ADA incidence
    0.7%
    non-GLP-1 comparators

    Source sentences

    Summary
    A total of 64 dulaglutide-treated patients (1.6% of the population) tested ADA-positive versus eight (0.7%) from the non-GLP-1 comparator group.
    1 context sentence
    Summary · context
    The present study assessed the incidence of treatment-emergent dulaglutide ADAs, hypersensitivity AEs, injection site reactions (ISRs), and glycaemic control in ADA-positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non-GLP-1 comparators, N = 1141).
  2. 02HumanObservational studySafety outcome

    Dulaglutide-neutralizing antibodies occurred in 34 treated patients, reported as 0.9%.

    In plain wordsAntibodies that neutralized dulaglutide occurred in 34 patients.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDulaglutide-neutralizing antibodies
    Study

    n = 4,006

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Neutralizing ADAs
    34 patients
    dulaglutide
    Neutralizing ADA incidence
    0.9%
    dulaglutide

    Source sentences

    Summary
    Of these 64 patients, 34 (0.9%) had dulaglutide-neutralizing ADAs, 36 (0.9%) had native-sequence GLP-1 (nsGLP-1) cross-reactive ADAs and four (0.1%) had nsGLP-1 neutralization ADAs.
    1 context sentence
    Summary · context
    The present study assessed the incidence of treatment-emergent dulaglutide ADAs, hypersensitivity AEs, injection site reactions (ISRs), and glycaemic control in ADA-positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non-GLP-1 comparators, N = 1141).
  3. 03HumanObservational studySafety outcome

    Native-sequence GLP-1 cross-reactive antibodies occurred in 36 dulaglutide-treated patients, reported as 0.9%.

    In plain wordsAntibodies that also recognized natural GLP-1 occurred in 36 dulaglutide-treated patients.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNative GLP-1 cross-reactive antibodies
    Study

    n = 4,006

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Cross-reactive ADAs
    36 patients
    dulaglutide
    Cross-reactive ADA incidence
    0.9%
    dulaglutide

    Source sentences

    Summary
    Of these 64 patients, 34 (0.9%) had dulaglutide-neutralizing ADAs, 36 (0.9%) had native-sequence GLP-1 (nsGLP-1) cross-reactive ADAs and four (0.1%) had nsGLP-1 neutralization ADAs.
    1 context sentence
    Summary · context
    The present study assessed the incidence of treatment-emergent dulaglutide ADAs, hypersensitivity AEs, injection site reactions (ISRs), and glycaemic control in ADA-positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non-GLP-1 comparators, N = 1141).
  4. 04HumanObservational studySafety outcome

    Native-sequence GLP-1 neutralization antibodies occurred in four dulaglutide-treated patients, reported as 0.1%.

    In plain wordsAntibodies that neutralized natural GLP-1 occurred in four dulaglutide-treated patients.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNative GLP-1 neutralization antibodies
    Study

    n = 4,006

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    GLP-1 neutralization ADA incidence
    0.1%
    dulaglutide
    GLP-1 neutralization ADAs
    4 patients
    dulaglutide

    Source sentences

    Summary
    Of these 64 patients, 34 (0.9%) had dulaglutide-neutralizing ADAs, 36 (0.9%) had native-sequence GLP-1 (nsGLP-1) cross-reactive ADAs and four (0.1%) had nsGLP-1 neutralization ADAs.
    1 context sentence
    Summary · context
    The present study assessed the incidence of treatment-emergent dulaglutide ADAs, hypersensitivity AEs, injection site reactions (ISRs), and glycaemic control in ADA-positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non-GLP-1 comparators, N = 1141).
  5. 05HumanObservational studySafety outcome

    No dulaglutide ADA-positive patient reported hypersensitivity adverse events.

    In plain wordsNo patient with dulaglutide antibodies reported an allergic reaction.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypersensitivity in ADA-positive patients
    Study

    n = 64

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No dulaglutide ADA-positive patient reported hypersensitivity AEs.
    1 context sentence
    Summary · context
    A total of 64 dulaglutide-treated patients (1.6% of the population) tested ADA-positive versus eight (0.7%) from the non-GLP-1 comparator group.
  6. 06HumanObservational studySafety outcome

    Hypersensitivity adverse event incidence was similar with dulaglutide and placebo.

    In plain wordsAllergic reactions occurred at similar rates with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHypersensitivity adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The incidence of hypersensitivity AEs and ISRs was similar in the dulaglutide versus placebo groups.
  7. 07HumanObservational studySafety outcome

    Injection site reaction incidence was similar with dulaglutide and placebo.

    In plain wordsInjection site reactions occurred at similar rates with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeInjection site reactions
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The incidence of hypersensitivity AEs and ISRs was similar in the dulaglutide versus placebo groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.